Trial Update November 10, 2026

Dulaglutide Trial on Endoscopy Prep Listed as Not Yet Recruiting

A new clinical trial involving dulaglutide was registered, with an update recorded on November 10, 2026. The study, titled "24-hour Clear Liquid Diet vs. Standard Fasting for Upper Gastrointestinal Endoscopy in Patients Taking Agonists of the GLP-1 Receptor," is listed under identifier NCT07929233. The trial's current status is not yet recruiting. No phase is assigned to this study, as it is listed as phase NA.

The trial aims to compare two pre-procedure dietary protocols, a 24-hour clear liquid diet and standard fasting, in patients taking GLP-1 receptor agonists ahead of upper gastrointestinal endoscopy. Dulaglutide is included among the GLP-1 receptor agonists relevant to this patient population. As the study has not yet begun recruiting participants, no enrollment, interim, or outcome data are available at this time.

Further details on the trial's design, eligibility criteria, and timeline can be found in its public registry listing. Updates to the study's recruitment status will be reflected in future registry records as they become available.

Readers interested in additional background may consult the compound overview for context on dulaglutide.

See the full dulaglutide overview

Source: https://clinicaltrials.gov/study/NCT07929233